💊 HLA-B*5701 Abacavir Hypersensitivity Screen

Pre-Prescription Sample Collection for HLA Genotyping

Abacavir (ABC), a guanosine nucleoside reverse transcriptase inhibitor used in HIV-1 antiretroviral therapy, causes a severe, sometimes fatal, immune-mediated hypersensitivity reaction in a genetically defined subset of patients. Because this reaction is essentially eliminated by testing before the first dose, HLA-B*5701 screening is one of the earliest and most successful examples of pharmacogenomics translated into routine standard-of-care medicine.

• 5–8%: AHR incidence (untested, historical) (of patients starting abacavir)
• <0.5%: AHR incidence (B*5701 negative) (residual, non-immunologic)
• 2008: FDA label mandate (boxed warning, test required)
• Buccal / EDTA blood: Specimen type (2–3 mL or swab, room-temp stable)

Why abacavir hypersensitivity demanded a genetic test

Abacavir hypersensitivity reaction (AHR) typically presents within the first 6 weeks of therapy (median onset 9 days) with fever, rash, gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal pain), and malaise — a constellation easily confused with a viral syndrome or other drug reactions. The critical danger is not the initial reaction but re-challenge: patients who are inadvertently re-exposed after a first reaction can develop a rapid, severe, and occasionally fatal hypotensive reaction within hours.

Before genetic screening, clinicians relied on symptom-based diagnosis alone, which has poor specificity — many patients were incorrectly labeled "hypersensitive" and denied a well-tolerated, once-daily drug, while true reactions were sometimes missed until re-challenge. The discovery in 2002 (Mallal et al., and Hetherington et al., Lancet) that AHR was almost perfectly restricted to carriers of the HLA-B*5701 allele transformed abacavir from a drug requiring cautious clinical judgment into one governed by a simple, deterministic pre-treatment test.

The PREDICT-1 trial (Mallal et al., NEJM 2008, n=1,956) demonstrated that prospective HLA-B*5701 screening reduced immunologically confirmed AHR from 2.7% to 0% in the screened arm — a rare case of a pharmacogenomic test converting a serious drug reaction risk to effectively zero.

Specimen collection and pre-analytical requirements

Sample collection for HLA-B genotyping is deliberately simple to maximize uptake before first prescription:

• Buccal swab: two flocked swabs rotated against the inner cheek for 30 seconds; yields ~1–5 µg genomic DNA from epithelial cells, sufficient for PCR-based typing; preferred in outpatient/rural clinics for logistics • EDTA whole blood: 2–3 mL venous draw (purple-top tube); preferred by reference laboratories performing SBT or NGS-based typing, as it yields higher-quality, higher-quantity DNA (10–30 µg) • Samples are stable at room temperature for 24–72 h (buccal) or refrigerated for blood, permitting mail-in testing to centralized reference labs • Chain-of-custody and patient identifiers are critical: a mislabeled sample resulting in a false-negative report could lead to a preventable, potentially fatal hypersensitivity reaction

Because the result is a permanent, one-time genetic attribute (HLA-B genotype does not change over a patient's lifetime), testing is performed once and the result is entered into the medical record analogous to a drug allergy — it should never need to be repeated.

Guideline mandates and global adoption

HLA-B*5701 screening prior to abacavir initiation is mandated or strongly recommended by essentially every major HIV treatment guideline body:

• US DHHS Antiretroviral Guidelines: abacavir contraindicated without a documented negative HLA-B*5701 result • FDA prescribing information: boxed warning since 2008 requiring screening • European AIDS Clinical Society (EACS) and WHO: equivalent recommendations • CPIC (Clinical Pharmacogenetics Implementation Consortium): Level A (highest) evidence guideline for HLA-B genotype-guided abacavir therapy

This universal mandate makes HLA-B*5701 the single most widely implemented pharmacogenomic test in infectious disease medicine, and it is frequently cited as the template proving that genotype-guided prescribing is operationally feasible at scale — turnaround time, cost (~$100–200 per test), and clinical workflow integration have all been solved and validated over more than 15 years of routine use.

HLA-B Locus Amplification and Allele-Specific Probe Hybridization

The HLA-B gene, located in the class I region of the Major Histocompatibility Complex on chromosome 6p21.3, is the single most polymorphic gene in the human genome, with over 7,500 known alleles catalogued in the IMGT/HLA database. Resolving one specific allele — B*5701 — against this staggering background diversity requires assays purpose-built for allele-level discrimination, not simple sequence variant calling.

• >7,500: HLA-B alleles catalogued (IMGT/HLA) (most polymorphic human gene)
• 2 & 3: Exons genotyped (encode peptide-binding groove)
• ~100+: PCR-SSO probe panel size (sequence-specific oligo probes)
• 4-digit: Typing resolution required (B*57:01 vs B*57:02/03 discrimination)

PCR-sequence-specific oligonucleotide (PCR-SSO) typing

The workhorse clinical assay for HLA-B*5701 screening is PCR-SSO, commercialized in platforms such as Luminex-based LABType SSO and One Lambda kits:

1. Locus-specific PCR amplifies exons 2 and 3 of HLA-B (encoding the α1 and α2 domains that form the peptide-binding groove) using group-specific primers and biotinylated nucleotides 2. The biotin-labeled amplicon is denatured and hybridized to a panel of >100 fluorescently color-coded microspheres, each coated with a distinct sequence-specific oligonucleotide probe complementary to a known HLA-B polymorphism 3. Streptavidin-phycoerythrin conjugate binds hybridized biotinylated amplicon, generating a fluorescent signal only on beads where the probe matched 4. Flow-based Luminex reader (xMAP technology) measures bead color (identifies probe) and PE signal intensity (confirms hybridization) for all beads simultaneously 5. Proprietary software cross-references the pattern of positive/negative probes against the IMGT/HLA allele database to assign genotype

An alternative widely used platform is real-time PCR with sequence-specific primers and melting-curve analysis (e.g., the Invader HLA-B*57 assay or TaqMan-based allelic discrimination), which specifically targets the B*57:01 rs2395029 tag SNP (in near-complete linkage disequilibrium with B*5701) for a faster, lower-cost binary result in ~2-3 hours.

Because B*5701 shares many sequence motifs with closely related alleles (B*5702, B*5703, common in African populations, which do NOT confer AHR risk), probe panels must include exon 3 discriminating probes — early single-exon assays risked false-positive calls that would unnecessarily exclude patients from an effective, convenient drug.

Sequence-based typing (SBT) and NGS confirmation

For ambiguous PCR-SSO patterns, or as the primary method in reference and research laboratories, Sanger sequence-based typing (SBT) or next-generation amplicon sequencing resolves the exact allele:

• Group-specific PCR amplifies exons 2-4 with locus-specific primers; both DNA strands are sequenced • Sequencing electropherograms are analyzed with SBT-specific software (uTYPE, Assign) against the IMGT/HLA reference to call heterozygous/homozygous genotypes • Phase ambiguity (cis/trans heterozygote combinations that give identical mixed base calls) can require group-specific sequencing primers or long-read NGS (PacBio/Oxford Nanopore full-length HLA sequencing) to fully resolve • NGS-based HLA typing (e.g., Illumina MiSeq amplicon panels covering exons 2-4, or whole-gene long-read sequencing) increasingly replaces SBT in high-throughput reference laboratories, offering 2-field (4-digit) resolution at lower per-sample cost and full allele phasing

Regardless of platform, the clinical report distills this complex molecular typing down to a single actionable binary output: HLA-B*5701 detected or not detected — deliberately simplified for prescriber decision-making at the point of care.

Rapid tag-SNP genotyping alternative

For settings requiring faster turnaround, single nucleotide polymorphism (SNP) genotyping of the tag SNP rs2395029 (HCP5 gene, in near-perfect linkage disequilibrium with HLA-B*5701, r²≈0.97 in European ancestry populations) offers a cost-effective proxy:

• TaqMan allelic discrimination or PCR-melting curve assays interrogate this single SNP in under 2 hours • Because LD between rs2395029 and B*5701 varies by ancestry (weaker in some African populations), tag-SNP methods are generally reserved for populations where LD has been validated, or used as a rapid first-pass screen with confirmatory PCR-SSO/SBT for positive results • Point-of-care and pharmacy-based rapid tests are in development to shorten the pre-prescription window from days to hours in urgent-start ART settings

Genotype Calling and IMGT/HLA Database Reconciliation

Converting raw hybridization or sequencing signal into a clinically reportable genotype call requires cross-referencing against the continuously curated IMGT/HLA database and applying strict quality thresholds — a single miscall in either direction carries real clinical consequences, from unwarranted drug exclusion to a preventable hypersensitivity reaction.

• 3–5 days: Turnaround time (standard) (reference laboratory)
• 2–4 hours: Turnaround time (rapid SNP) (point-of-care assays)
• >99%: Analytical sensitivity/specificity (PCR-SSO vs SBT gold standard)
• ≥2 independent: Required probe concordance (exons/probes per positive call)

Quality control and the binary clinical report

Clinical HLA genotyping laboratories operate under CLIA/CAP (or equivalent national) accreditation with strict quality metrics:

• Each run includes positive controls (known B*5701-positive cell line DNA, e.g. IHW cell panel reference material) and negative controls • A call is only reported when probe/signal patterns unambiguously match a single interpretation in the IMGT/HLA database — discordant or borderline signals trigger repeat testing or reflex to SBT/NGS • Inter-laboratory proficiency testing (College of American Pathologists HLA survey) confirms >99% concordance across methods for B*5701 calls specifically • The final clinical report states only: "HLA-B*5701: Positive" or "HLA-B*5701: Negative" — the underlying 4-digit full genotype (e.g., B*57:01:01/B*08:01:01) is retained in the lab record but the prescriber-facing report is deliberately reduced to the single actionable data point

This simplification is a deliberate design choice in translational pharmacogenomics: burying prescribers in genotype detail increases the chance of misinterpretation, whereas a binary contraindication flag integrates cleanly into electronic health record clinical decision support (CDS) alerts.

Population allele frequency and pre-test probability

HLA-B*5701 prevalence varies substantially by ancestry, which affects both the pre-test probability of a positive result and historical rates of AHR before screening was universal:

• European ancestry: ~5–8% carrier frequency • Hispanic/Latino: ~3–5% • African/African-American: ~1–2.5% • East Asian: <1% (rare) • South Asian: ~2–3% • Highest reported: certain populations in India and the Middle East, up to 10–20% in isolated cohorts

Because the allele is common enough to matter clinically across all ancestries yet variable enough that "eyeballing" risk by ethnicity is unreliable and inequitable, universal genotyping — rather than selective testing based on ancestry — is the guideline-endorsed standard of care, ensuring equal protection regardless of a patient's background.

Linkage with the extended ancestral haplotype 57.1

HLA-B*5701 is not typically found in isolation; it exists within a large, highly conserved linkage block termed the ancestral haplotype 57.1 (AH57.1), spanning several megabases across the MHC and including HLA-C*06:02, HLA-DRB1*07:01, and the tag SNP rs2395029 in HCP5 (an endogenous retrovirus-derived long non-coding RNA gene near HLA-B).

This extended linkage disequilibrium is precisely why the rapid tag-SNP proxy assays work: rs2395029 essentially never recombines away from B*5701 within populations of predominantly European ancestry, making it a reliable, cheaper genotyping shortcut. The same AH57.1 haplotype has also been associated with other immune phenotypes (e.g., certain autoimmune associations), an active area of ongoing haplotype-disease research beyond abacavir.

Altered Peptide Repertoire — How B*5701 Converts Abacavir into a Neo-Antigen

HLA-B*5701 screening would be a purely statistical curiosity without a mechanistic explanation for why this exact allele — and essentially only this allele — drives a drug reaction. Structural immunology work over the past 15 years has resolved the mechanism in atomic detail: abacavir does not act as a classical hapten, but instead reshapes the very population of self-peptides that HLA-B*5701 presents to the immune system.

• F-pocket: HLA-B*5701 peptide groove pocket (C-terminal anchor residue site)
• ~20–45%: Self-peptide repertoire altered (novel peptides presented with drug)
• 9 days: Onset of symptoms after first dose (median; range 1–6 weeks)
• CD8+: T-cell subset activated (cytotoxic, drug-specific clones)

The altered peptide repertoire model

The landmark structural studies (Illing et al., Nature 2012; Norcross et al., AIDS 2012) resolved crystal structures of HLA-B*5701 in complex with abacavir and bound self-peptides, revealing the mechanism:

• Abacavir binds non-covalently but with high affinity within the F-pocket of the HLA-B*5701 peptide-binding groove — the pocket that normally accommodates the C-terminal anchor residue of presented peptides • The F-pocket of B*5701 has a uniquely shaped, hydrophobic cavity (due to specific polymorphic residues at positions 97, 114, 116, 156) that snugly accommodates the abacavir molecule — this shape complementarity is essentially allele-specific, explaining why closely related alleles like B*5702/5703 (differing by a few residues) do not bind the drug the same way • With abacavir occupying the F-pocket, the chemistry and shape requirements for peptides able to bind HLA-B*5701 change: peptides that could never be presented before the drug now fit, while some normal self-peptides are excluded • The result is a qualitatively new "neo-peptidome" — an estimated 20–45% novel repertoire of self-peptide/HLA-B*5701 complexes displayed on the cell surface, none of which the thymus ever screened T-cells against during central tolerance induction

This is a fundamentally different drug-reaction mechanism than classical hapten hypersensitivity (e.g., penicillin): abacavir does not need to covalently modify a peptide or protein. It simply changes the shape of the HLA groove itself, making an entirely new set of "self" peptides look foreign to the immune system — a mechanism now generalized as the "altered repertoire" model of HLA-linked drug hypersensitivity, also implicated in carbamazepine-HLA-B*1502 and allopurinol-HLA-B*5801 reactions.

CD8+ T-cell priming and the clinical hypersensitivity cascade

Because the neo-peptides presented in the presence of abacavir were never encountered during thymic negative selection, circulating naive CD8+ T-cells with T-cell receptors (TCRs) reactive to these novel p-HLA-B*5701 complexes have not been deleted from the repertoire:

1. Dendritic cells and other antigen-presenting cells expressing HLA-B*5701, exposed to systemic abacavir, begin displaying the altered self-peptide repertoire on their surface 2. Naive, high-avidity CD8+ T-cell clones recognize these complexes as foreign and undergo activation and clonal proliferation — in vitro, abacavir-responsive CD8+ T-cell clones can be expanded from PBMCs of B*5701-positive individuals within days 3. Clonally expanded, cytotoxic CD8+ T-cells infiltrate skin and other tissues, releasing pro-inflammatory cytokines (IFN-γ, TNF-α) and cytotoxic mediators (granzyme B, perforin), producing the clinical syndrome: fever, maculopapular rash, malaise, GI symptoms, and rarely, respiratory distress 4. Because this is genuine, durable T-cell memory, re-exposure after even a brief interruption triggers a much faster, more severe reaction — the basis for the absolute, lifelong contraindication rather than a "try again cautiously" approach

Structural specificity — why only B*5701 (not 5702/5703)

Comparative crystallography between HLA-B*5701 and its close structural relatives explains the near-perfect allele specificity of AHR:

• B*5701 vs B*5702: differ by a small number of residues within the peptide-binding groove, but critically these differences alter F-pocket geometry enough that abacavir binding affinity drops substantially • B*5701 vs B*5703 (common in sub-Saharan African populations): similarly altered pocket residues abolish the drug-induced repertoire shift despite overall high sequence homology • This explains a clinically important and initially puzzling epidemiological observation: African populations, despite carrying HLA-B*57 alleles at meaningful frequency, show far lower rates of B*5701 specifically (favoring 5702/5703 instead) and correspondingly lower historical AHR rates — reinforcing why 4-digit (not 2-digit "B*57") resolution genotyping is clinically mandatory, not merely a technical nicety

From Genotype to Prescription — Closing the Pharmacogenomic Loop

The final and most consequential step of the HLA-B*5701 screen is not a laboratory assay at all — it is the translation of a molecular result into an irreversible prescribing decision at the point of care. This last-mile step is where pharmacogenomic testing programs succeed or fail in practice, and HLA-B*5701/abacavir remains the most successful and durable example of getting it right.

• ~0%: AHR with screening (real-world) (immunologically confirmed cases)
• ~13–20: NNT to prevent one AHR case (number needed to test)
• Level A: CPIC guideline level (strongest actionability grade)
• >15: Years in continuous clinical use (since 2008 FDA label update)

Electronic health record clinical decision support

Modern implementation embeds the binary HLA-B*5701 result directly into e-prescribing systems:

• A positive result triggers a hard-stop or interruptive alert if a clinician attempts to order abacavir or any fixed-dose combination containing it (e.g., abacavir/lamivudine, abacavir/dolutegravir/lamivudine) • The result is coded analogous to a severe drug allergy in the allergy/intolerance section of the chart — not filed only as a lab result that could be overlooked • Because the genotype never changes, this single test result should protect the patient across every future abacavir prescribing decision, at every institution with EHR interoperability, for life • Discordance between test result and prescribing (i.e., a positive patient nonetheless prescribed abacavir) is now tracked as a serious medication safety/quality metric in many health systems

Alternative regimen selection for positive patients

A positive HLA-B*5701 result does not leave patients without options — modern antiretroviral therapy has multiple effective NRTI backbones and even NRTI-sparing regimens:

• Tenofovir-based backbones (tenofovir disoproxil fumarate/emtricitabine or tenofovir alafenamide/emtricitabine) are the most common substitution, with comparable efficacy and a different, favorable toxicity profile • Integrase strand transfer inhibitor (INSTI)-based regimens without abacavir (e.g., bictegravir/emtricitabine/tenofovir alafenamide) are now frequently first-line regardless of HLA status, somewhat reducing dependence on the abacavir-specific screen but not eliminating its importance for the abacavir-containing regimens that remain preferred in specific populations (e.g., renal impairment, where abacavir is favored over tenofovir) • The screening result also has downstream relevance beyond HIV: HLA-B*5701 testing workflows and infrastructure built for abacavir are directly reused for other HLA-linked pharmacogenomic tests (HLA-B*1502/carbamazepine, HLA-B*5801/allopurinol, HLA-A*3101/carbamazepine), making this program a template for the broader field

Cost-effectiveness and program-level outcomes

Health-economic analyses consistently support universal HLA-B*5701 screening as cost-effective or even cost-saving:

• Test cost (~$100–200) is far lower than the cost of managing a hospitalized hypersensitivity reaction, which can include emergency department visits, IV fluids/steroids, and rarely ICU-level care for severe reactions • Number needed to test (NNT) to prevent one clinically significant AHR case is estimated at 13–20 in populations with typical B*5701 prevalence, a highly favorable ratio for a one-time, lifelong-informative test • Beyond direct cost, screening prevents the "false hypersensitivity" problem: patients incorrectly labeled intolerant based on symptoms alone (which overlap with common viral illness) who were needlessly denied a well-tolerated once-daily regimen — genetic confirmation resolves diagnostic ambiguity definitively

HLA-B*5701 testing before abacavir is frequently cited in pharmacogenomics education and policy as the single clearest proof-of-concept that genotype-guided prescribing works in unselected, real-world clinical populations — not just in controlled trials — and it remains the benchmark against which newer pharmacogenomic implementation programs (e.g., CYP2D6-guided opioid dosing, DPYD-guided fluoropyrimidine dosing) are measured.